Pregabalin Misuse–Related Issues; Intake of Large Dosages, Drug-Smoking Allegations, and Possible Association With Myositis: Two Case Reports
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
To the Editors Pregabalin is a gamma-aminobutyric acid analog that is approved for the treatment of epilepsy, neuropathic pain, and generalized anxiety disorder. However, it has been anecdotally reported from the United States,1 Germany,2 Sweden,3 and Norway4 that the molecule may possess a potential of misuse. Pregabalin is widely described online by users as an “ideal psychotropic drug” for recreational purposes.5 In line with this, pregabalin has recently been included in the list of new recreational psychoactive substances officially notified to the relevant European Union agencies.6 We present here the first 2 cases of pregabalin misuse identified in southern Europe; they highlight a few related concerns, including intake of large dosages, allegations of drug smoking, and possible occurrence of myositis. CASE REPORTS Case 1 Patient 1, a 32-year-old white European, was referred to the local National Health Service outpatient drug treatment unit for issues related to pregabalin misuse. The case patient had a previous diagnosis of antisocial personality disorder and reported a history of benzodiazepines, cocaine, and ecstasy abuse. Because of a diagnosis of a neuropathic pain condition, his general practitioner started him on a pregabalin daily dosage of 75 mg 2 times a day (BD), which was then increased to 150 mg BD by day 5 and to 300 mg BD by day 12. Roughly over the following 4 weeks, however, the patient gradually increased the dosage up to an alleged daily amount of 4500 mg. He managed to get access to these levels of pregabalin tablets either through a new general practitioner’s prescription or obtaining it from a friend. At the same time, he was misusing with both alcohol and cannabis. On a few occasions, he tried to discontinue his pregabalin intake, but as a result was feeling anxious, extremely irritable, and aggressive. Conversely, in association with his pregabalin intake, he was feeling more relaxed, “more empathetic,” and with “very good drive.” He was describing his life before pregabalin initiation as “extremely boring” and characterized by constant feelings of anger. At admission, the urine toxicology specimen was positive only for cannabis. The pregabalin dosage was gradually reduced, and benzodiazepines were introduced to control the case patient’s withdrawal signs and symptoms. However, after a few days, the patient dropped out of treatment. Case 2 Patient 2, a 33-year-old white European, was referred to the local National Health Service outpatient psychiatric unit for issues related to both his bipolar and generalized anxiety disorder conditions. Because of these, he was prescribed olanzapine, 10 mg/d, and was started with pregabalin, 75 mg once a day. Pregabalin was then increased to 75 mg BD by day 3 and to 150 mg BD by day 8. Up to 5 years before, he was misusing with ecstasy and alcohol. At admission, his urine toxicology specimen was positive for cannabis only. Over the first few days of pregabalin intake, he was feeling increasingly relaxed, emphasizing that the pregabalin effects were “very similar to those of cannabis.” As a result, over the first 4 weeks or so, he gradually increased the dosage up to 1500 mg, feeling as being “under the influence of an anesthetic,” and “very light.” To achieve both a quicker and more intense effect, he also tried to smoke the crushed pregabalin tablets. He allegedly obtained the extra pregabalin tablets from a friend. Over time, however, he developed an intense muscle pain, as he had “severely torn his leg muscle.” Although unfortunately, CPK levels were not made available, a tentative diagnosis of myositis was made, with causes different from pregabalin intake having been ruled out by both clinical interview and full medication review. The Naranjo Probability Scale7 indicated a probable relationship between pregabalin intake and the onset of myositis. Pregabalin was gradually discontinued, and benzodiazepines were introduced to control the observed increase in both anxiety and craving levels. The muscular pain disappeared over a week. DISCUSSION The case reports here described suggest that pregabalin experimenters might be profiled as individuals with a history of recreational polydrug, including ecstasy, misuse and, as such, confirming previous observations.5 Pregabalin dosages reported here, especially in case 1, were clearly a reason of concern and certainly in excess of the advised daily maximum level (eg, 600 mg).8 Overall, the misuse of pregabalin mostly seem to occur orally, but intravenous, rectal (“plugging”), and “parachuting” (emptying the content of the capsule into a pouch) self-administration techniques have been described as well.5 However, patient 2 allegedly tried to smoke an unconfirmed amount of pregabalin crushed tablets, a technique, which to the best of our understanding, had never been reported before. In both cases, the patients were started with pregabalin for medical reasons. However, because of the rapid developme
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, olanzapine high-dosage has been anecdotally reported as the 'ideal trip terminator/modulator' (49)(50).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [49]
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Schifano, F., D’Offizi, S., Piccione, M., Corazza, O., Deluca, P., Davey, Z., Di Melchiorre, G., Di Furia, L., Farré, M., Flesland, L., et al. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000321079 · Cited by 187
Self-citationSchwan, S., Sundström, A., Stjernberg, E., Hallberg, E., & Hallberg, P. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0853-y · Cited by 169
Drugs on the web; the Psychonaut 2002 EU project
Schifano, F., Deluca, P., Baldacchino, A., Peltoniemi, T., Scherbaum, N., Torrens, M., Farré, M., Flores, I., Rossi, M., Eastwood, D., et al. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.035 · Cited by 112
Self-citationPregabalin Abuse, Dependence, and Withdrawal: A Case Report
Grosshans, M., Mutschler, J., Hermann, D., Klein, O., Dreßing, H. R., Kiefer, F., & Mann, K. F. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091269 · Cited by 108
Martinotti, G., Di Nicola, M., Frustaci, A., Romanelli, R., Tedeschi, D., Guglielmo, R., Guerriero, L., Bruschi, A., De Filippis, R., Pozzi, G., et al. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02792.x · Cited by 83
Potential for pregabalin abuse or diversion after past drug-seeking behavior.
Filipetto, F. A., Zipp, C. P., & Coren, J. S. (2010) · PubMed · Cited by 81
Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial
Martinotti, G., Di Nicola, M., Tedeschi, D., Andreoli, S., Reina, D., Pomponi, M., Mazza, M., Romanelli, R., Moroni, N., De Filippis, R., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109102623 · Cited by 81
Internet pharmacies and online prescription drug sales: a cross-sectional study
Littlejohn, C., Baldacchino, A., Schifano, F., & Deluca, P. (2005) · Drugs Education Prevention and Policy · doi:10.1080/0968763042000275326 · Cited by 80
Self-citationHadley, S. J., Mandel, F. S., & Schweizer, E. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111405360 · Cited by 66
Research works printed but not linked: 1
- Nymdelger, 2007, Pregabalin: a neuromodulator for the treatment of neuropathic pain, generalized anxiety disorders and cystic fibrosis syndrome., Medizin Monatssch Pharmazeuten, 30, 396
Cited by
Abuse and Misuse of Pregabalin and Gabapentin
Evoy, K. E., Morrison, M. D., & Saklad, S. R. (2017) · Drugs · doi:10.1007/s40265-017-0700-x · Cited by 410
How addictive are gabapentin and pregabalin? A systematic review
Bonnet, U., & Scherbaum, N. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.430 · Cited by 281
Misuse and Abuse of Pregabalin and Gabapentin: Cause for Concern?
Schifano, F. (2014) · CNS Drugs · doi:10.1007/s40263-014-0164-4 · Cited by 250
Self-citationChiappini, S., & Schifano, F. (2016) · CNS Drugs · doi:10.1007/s40263-016-0359-y · Cited by 189
Self-citationAbuse Potential of Pregabalin: A Systematic Review
Schjerning, O., Rosenzweig, M., Pottegård, A., Damkier, P., & Nielsen, J. (2016) · CNS Drugs · doi:10.1007/s40263-015-0303-6 · Cited by 162
Legal highs: staying on top of the flood of novel psychoactive substances
Baumeister, D., Tojo, L. M., & Tracy, D. K. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314559539 · Cited by 159
Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance
Tambon, M., Ponté, C., Jouanjus, É., Sam‐Laï, N. F., Micallef, J., Lapeyre‐Mestre, M., & the French Addictovigilance Network (FAN) (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.639780 · Cited by 78
The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview
Martinotti, G., Lupi, M., Sarchione, F., Santacroce, R., Salone, A., Berardis, D., Serroni, N., Cavuto, M., Signorelli, M., Aguglia, E., et al. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990425 · Cited by 72
Pregabalin Misuse and Abuse in Jordan: a Qualitative Study of User Experiences
Al-Husseini, A., Wazaify, M., & Hout, M. C. V. (2017) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-017-9813-4 · Cited by 69
Factors associated with pregabalin dispensing at higher than the approved maximum dose
Bodén, R., Wettermark, B., Brandt, L., & Kieler, H. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1594-5 · Cited by 64
Concerns About Pregabalin: Further Experience With Its Potential of Causing Addictive Behaviors
Gahr, M., Franke, B., Freudenmann, R. W., Kölle, M. A., & Schönfeldt‐Lecuona, C. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3182872718 · Cited by 63
Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review
Freynhagen, R., Bačkonja, M., Schug, S. A., Lyndon, G. J., Parsons, B., WATT, S. J., & Behar, R. (2016) · CNS Drugs · doi:10.1007/s40263-016-0390-z · Cited by 60
Jebadurai, J. K. (2013) · University of Hertfordshire Research Archive (University of Hertfordshire) · doi:10.18745/th.11352 · Cited by 45
Jebadurai, J. K., Schifano, F., & Deluca, P. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2302 · Cited by 43
Self-citationPregabalin serum levels in apprehended drivers
Kriikku, P., Wilhelm, L., Rintatalo, J., Hurme, J., Kramer, J., & Ojanperä, I. A. (2014) · Forensic Science International · doi:10.1016/j.forsciint.2014.06.030 · Cited by 38
Taha, S. H. N., Zaghloul, H. S., Ali, A. A., Gaballah, I. F., Rashed, L. A., & Aboulhoda, B. E. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01875-5 · Cited by 32
Intravenous Administration and Abuse of Bupropion: A Case Report and a Review of the Literature
Oppek, K., Koller, G., Zwergal, A., & Pogarell, O. M. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000044 · Cited by 31
Shokry, D. A., Nabrawy, N. E., Yassa, H. D., Gaber, S. S., Batiha, G. E., & Welson, N. N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118344 · Cited by 27
Pregabalin Dependence: A Case Report
Aldemir, E., Altintoprak, E., & Çoşkunol, H. (2014) · Turkish Journal of Psychiatry · doi:10.5080/u7746 · Cited by 26
Francesconi, G., Orsolini, L., Papanti, D., Corkery, J. M., & Schifano, F. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2476 · Cited by 22
Self-citationÜber das Abhängigkeitspotential von Gabapentinoiden
Bonnet, U., & Scherbaum, N. (2017) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0043-122392 · Cited by 21
Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs
Schifano, F. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507897 · Cited by 18
Self-citationPrégabaline et risque d’addiction : une nouvelle demande de soin ?
Roche, S., & Blaise, M. (2020) · L Encéphale · doi:10.1016/j.encep.2020.02.008 · Cited by 18
GC‐MS/MS detects potential pregabalin abuse in susceptible subjects’ hair
Ianni, F., Aroni, K., Gili, A., Sardella, R., Bacci, M., Lancia, M., Natalini, B., & Gambelunghe, C. (2018) · Drug Testing and Analysis · doi:10.1002/dta.2347 · Cited by 17
Comparative Study of the Neurotoxic Effects of Pregabalin Versus Tramadol in Rats
Elsukary, A. E., Helaly, A. M., Bakary, A. A. E., Moustafa, M. E., & El-Kattan, M. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00557-9 · Cited by 16
Aktaş, S., Tetikoğlu, M., İnan, S., Aktaş, H., & Özçura, F. (2016) · Cutaneous and Ocular Toxicology · doi:10.3109/15569527.2016.1141420 · Cited by 16
Taha, S. H. N., Zaghloul, H. S., Ali, A. A., Rashed, L. A., Sabry, R. M., & Gaballah, I. F. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05894-6 · Cited by 15
Pregabalin abuse in adolescence: a case series
Alan, B. E., Kızılkan, M. P., & Akgül, S. (2022) · The Turkish Journal of Pediatrics · doi:10.24953/turkjped.2020.30 · Cited by 15
Garnier, C., Schein, M., Lacroix, C., Jouve, É., Soeiro, T., Gentile, G., Lapeyre‐Mestre, M., & Micallef, J. (2024) · CNS Drugs · doi:10.1007/s40263-024-01095-y · Cited by 12
Pregabalin Misuse and Abuse: A Scoping Review of Extant Literature
Al-Husseini, A., Hout, M. C. V., & Wazaify, M. (2018) · Journal of Drug Issues · doi:10.1177/0022042618759487 · Cited by 12
Lacroix, C., Frauger, É., Jouve, É., Peyrière, H., & Micallef, J. (2024) · Therapies · doi:10.1016/j.therap.2024.10.054 · Cited by 12
Mésusage de prégabaline : à propos de sept cas de décès en région marseillaise
Sastre, C., Baillif‐Couniou, V., Fabresse, N., Ameline, A., Kintz, P., Gaulier, J., Allorge, D., Piercecchi‐Marti, M., Léonetti, G., & Pélissier‐Alicot, A. (2022) · Annales de Toxicologie Analytique · doi:10.1016/j.toxac.2021.12.006 · Cited by 11
Pregabalin and addiction: lessons from published cases
Gahr, M., Freudenmann, R. W., Kölle, M. A., & Schönfeldt‐Lecuona, C. (2013) · Journal of Substance Use · doi:10.3109/14659891.2013.843725 · Cited by 8
From benzodiazepine to pregabalin dependence: Different agents, similar problems
Gahr, M., Freudenmann, R. W., Kölle, M. A., & Schönfeldt‐Lecuona, C. (2015) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.148551 · Cited by 8
Gabapentinoid Use Disorder: Update for Clinicians
Pergolizzi, J. V., Taylor, R. M., Bisney, J., LeQuang, J. A., Coluzzi, F., & Gharibo, C. G. (2018) · IRIS Research product catalog (Sapienza University of Rome) · Cited by 7
Ekici, Ö. Ç., Şahiner, İ. V., Erzın, G., Ocak, D., Şahiner, Ş. Y., & Göka, E. (2019) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2019.1673946 · Cited by 7
El-Kattan, M., Khattab, M. A., Maksoud, F. A., Eldein, M. E., Abdel-raof, N. E., Awad, W., & Elshatory, A. (2024) · Zagazig Journal of Forensic Medicine · doi:10.21608/zjfm.2023.218877.1154 · Cited by 6
Pregabalin Addiction: Case Report of a Young Adult
Chaudhary, N. C., & Jain, S. (2020) · International Healthcare Research Journal · doi:10.26440/ihrj/0403.06172 · Cited by 5
Elsayed, M., Zeiss, R., Gahr, M., Connemann, B. J., & Schönfeldt‐Lecuona, C. (2019) · Brain Sciences · doi:10.3390/brainsci9110322 · Cited by 5
Pregabalin addiction in a case with synthetic cannabinoid use
Köroğlu, G. (2017) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.5350/dajpn2017300108 · Cited by 4
Abdelghani, M., Fouad, A. A., Mamdouh, A., & Raya, Y. M. (2020) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0000000000000223 · Cited by 4
A case report of pregabalin use disorder with co-morbid somatic symptom disorder and depression
Saini, R., Panda, U. K., & Sarkar, S. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.11.033 · Cited by 4
Potential Benefits of N-Acetylcysteine in Preventing Pregabalin-Induced Seeking-Like Behavior
Almalki, A. H., Alsaab, H. O., Alsanie, W. F., Gaber, A., Alkhalifa, T., Almalki, A., Alzahrani, O., Grégio, A. M. T., Alhadidi, Q., Shah, Z. A., et al. (2021) · Healthcare · doi:10.3390/healthcare9040376 · Cited by 3
Seizures as an Adverse Effect of Pregabalin Consumption: A Systematic Review
Oskouei, Z., Moshiri, M., Rahmati, A. R., Nemati, A., Naeini, M. B., Jomehpour, H., Roohbakhsh, A., Salmasi, Z., & Etemad, L. (2025) · Addiction and Health · doi:10.34172/ahj.1527 · Cited by 2
Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction
(2021) · Frontiers research topics · doi:10.3389/978-2-88966-940-0 · Cited by 2
Gabapentin-induced sub-chronic neurotoxicity in rats and the protective role of alpha-tocopherol
El-Kattan, M., Saeed, E., Khattab, M. A., Maksoud, F. A., Eldein, M. E., Abdel-Roaf, N. E., Awad, W., & Elshatory, A. (2025) · Turkish Journal of Pathology · doi:10.5146/tjpath.2025.14236 · Cited by 2
Kriikku, P. (2015) · Helda - University of Helsinki Institutional Repository · Cited by 2
Pregabalin Abuse in between Jordanian youths need to concern
Obiesat, M. A., Marashdeh, M. F., Al-Zoubi, A. K., Al-Alwan, M. M., & Al-Odat, R. T. (2019) · International Journal of Scientific Research and Management (IJSRM) · doi:10.18535/ijsrm/v7i7.mp03 · Cited by 1
Heightened misuse risk and addictive potential of gabapentinoids: the fate of effective anxiolytics
Evren, C. (2019) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.14744/dajpns.2019.00013 · Cited by 1
Missbrauch und Abhängigkeit von Pregabalin (LYRICA®) unter Konsumenten illegaler Drogen
Snellgrove, B. J. (2016) · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) · doi:10.18725/oparu-4126 · Cited by 1
Zhang, Y. M. (2016) · TSpace (University of Toronto)
Pregabalin Misuse and Abuse in Jordan
Obiesat, M. A., Marashdeh, M. F., Al-Zoubi, A. K., Al-Alwan, M. M., & Al-Odat, R. T. (2018) · International Journal of Scientific Research and Management (IJSRM) · doi:10.18535/ijsrm/v6i3.mp04
Pregabalin abuse: Dependence, myositis and withdrawal symptoms: 2 case reports
(2013) · Reactions Weekly · doi:10.1007/s40278-013-6041-y
Abdel-raof, N. E., Khattab, M. M., Maksoud, F. A., Eldein, M. E., Elshatory, A., Awad, W., & El-Kattan, M. (2023) · The Egyptian Journal of Forensic Sciences and Applied Toxicology · doi:10.21608/ejfsat.2023.205239.1289
Garnier, C., & Shein, M. (2023) · HAL AMU
Gabapentin: a newly emerging drug of abuse, neurotoxicity, and potential addictive mechanisms
El-Kattan, M., Saeed, E., Khattab, M. A., Maksoud, F. A., Eldein, M. E., Abdel-Roaf, N. E., Awad, W., & Elshatory, A. (2026) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-026-00976-x
Daily Doses of Gabapentinoids for Pain Management Among Opioid Users Aged Below and Above 65 years
Zin, C. S., Alias, N. E., Abrar, N. H., Mubarak, N., & Shah, M. M. A. (2026) · Clinical Medicine & Research · doi:10.3121/cmr.2026.2028
Metadata
- Authors
- Carrus, D., & Schifano, F.
- Affiliations
- University of Hertfordshire (GB)
- ORCID
- Schifano, Fabrizio
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2012-12
- Volume
- 32
- Issue
- 6
- Pages
- 839-840
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2058884859
- Cited by
- 49
- References
- 13
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 4 · 2020: 6 · 2019: 2 · 2018: 2 · 2017: 7 · 2016: 4 · 2015: 4 · 2014: 4 · 2013: 7
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion)
- Funders
- European Commission
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- recreational drug use, myositis, GABA analogues, benzodiazepine withdrawal, antisocial personality disorder, cannabis use, alcohol consumption, neuropathic pain, polydrug use
- MeSH terms
- Pregabalin, Adult, gamma-Aminobutyric Acid, Humans, Male, Myositis, Smoking, Prescription Drug Misuse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.